...4-phenylbutyrate is approved as adjunctive therapy for the chronic management of UCD in the EU. Lucane Pharma S.A....

...it has Orphan Drug status. The product also has Orphan Drug designation in the U.S. Lucane Pharma S.A....

...Deltyba delamanid from Otsuka Pharmaceutical Co. Ltd. (Tokyo, Japan) and Para-aminosalicylic acid Lucane from Lucane Pharma S.A....

...financial terms, and Lucane could not be reached. Le Groupe Pharmaceutique Boivin , Montreal, Quebec Lucane Pharma S.A....

...designation in the EU for tuberculosis, is already available in France under a compassionate-use program. Lucane Pharma S.A....

...Deltyba delamanid from Otsuka Pharmaceutical Co. Ltd. (Tokyo, Japan) and Para-aminosalicylic acid Lucane from Lucane Pharma S.A....

...EMA's CHMP recommended approval of an MAA from Lucane Pharma for pheburane for adjunctive therapy in the...
...urea cycle disorders. The formulation of sodium 4-phenylbutyrate has Orphan Drug designation in the EU. Lucane Pharma S.A....

...to treat tuberculosis. PAS-GR is para-aminosalicylic acid. The company could not be reached for details. Lucane Pharma S.A....